Log In Get Started
Press Releases September 1, 2026 04:15 PM

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference

AnaptysBio to Present Financial Update at H.C. Wainwright 28th Annual Global Investment Conference

By Marcus Reed
Share
Twitter Reddit Facebook LinkedIn
ANAB

AnaptysBio announced that its CFO, Chris Murphy, will present at the H.C. Wainwright 28th Annual Global Investment Conference on September 15, 2026. The company manages financial collaborations for its drugs Jemperli with GSK and imsidolimab with Vanda, focusing on protecting and enhancing royalty value to shareholders. The live webcast offers investors direct insight into financial strategies and partnership progress.

Anaptys Announces Participation at the H.C. Wainwright 28th Annual Global Investment Conference
ANAB
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • AnaptysBio is emphasizing its financial collaborations with major pharmaceutical partners GSK (Jemperli) and Vanda (imsidolimab).
  • The presentation focuses on protecting and returning royalty value to shareholders, highlighting commitment to shareholder returns.
  • The event webcast provides transparency and direct communication to investors, supporting informed decision-making.

SAN DIEGO, Sept. 01, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a company focused on managing the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, today announced that Chris Murphy, chief financial officer, is scheduled to present at the H.C. Wainwright 28th Annual Global Investment Conference on Tuesday, Sept. 15, 2026. The presentation is scheduled to begin at 3:30pm ET.

A live webcast of the presentation will be available on the investor section of the Anaptys website at https://ir.anaptysbio.com/presentations-and-events. A replay of the webcast will be available for at least 30 days following the event.

About Anaptys

Anaptys manages the financial collaborations for Jemperli with GSK and imsidolimab with Vanda, with a focus on protecting and returning the value of its royalties to shareholders. To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.

Contact:
Chris Murphy
Chief Financial Officer
[email protected]


Risks

  • Dependence on successful partnerships with GSK and Vanda poses risk if collaborations falter or drug approvals underperform.
  • Royalty revenues may fluctuate based on market acceptance and commercial success of Jemperli and imsidolimab.
  • Presentation does not indicate new data or product milestones, which could limit immediate investor excitement.

More from Press Releases

UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights Nov 4, 2026 BioVie Announces Pricing of $4.74 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules Nov 4, 2026 Jasper Therapeutics Announces 1-for-30 Reverse Stock Split Nov 4, 2026 Twin Disc Announces First Quarter Results Nov 4, 2026 UniFirst Declares Increased Cash Dividends Oct 30, 2026